Atara Biotherapeutics, Inc.(ATRA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Atara Biotherapeutics, Inc. (ATRA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ATRA at 8.1/100 on a 32-signal composite quality model, placing it at rank #2,936 of 2,962 stocks — the bottom half of the AI-ranked universe. ATRA scores in the top quartile across institutional flow (93.6). Areas of concern include revenue growth (0.3) and revenue scale (1.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 18.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Atara Biotherapeutics, Inc. reports quarterly revenue of $630.0K, net income of $-4.8M. Top institutional holders of ATRA by reported 13-F value include EcoR1 Capital, ADAGE CAPITAL PARTNERS GP, L.L.C., Point72 Asset Management, L.P., based on the most recent SEC filings. ATRA trades on the Nasdaq exchange and files with the SEC under CIK 1604464. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ATRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Atara Biotherapeutics, Inc. directly from SEC EDGAR.